{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003866","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.197842+00:00","generated_at":"2026-06-07T02:09:53.184104+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Travere reports preliminary Q4 2023 net product sales ~$40M, FILSPARI sales $15M; cash $567M","bullets":["Preliminary Q4 2023 net product sales from continuing ops ~$40M; FY 2023 ~$128M.","FILSPARI net sales Q4 ~$15M (launch-to-date ~$30M); 459 new patient start forms in Q4.","Cash, cash equivalents & marketable securities ~$567M; expected to fund operations into 2028.","sNDA for full FILSPARI approval in IgAN on track for Q1 2024; CHMP opinion also expected Q1 2024.","Pivotal Phase 3 HARMONY study for pegtibatinase in HCU initiated; topline results expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003866","json":"https://secwatch.observer/filing/0001193125-24-003866.json","markdown":"https://secwatch.observer/filing/0001193125-24-003866.md","text":"https://secwatch.observer/filing/0001193125-24-003866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/d87492d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:09:53.184104+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdc760a56639fd5704990929245c3fcbbbf77219","claim":"Travere Therapeutics, Inc. reported fiscal year 2023 results: revenue approximately $128 million.","evidence_excerpt":"For the fiscal year 2023, the Company expects net product sales from continuing operations to be approximately $128 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"approximately $128 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"ddf5890e9cfb31c016d19a410a1fb46587e13ff5","claim":"Travere Therapeutics, Inc. reported fourth quarter of 2023 results: revenue $15 million.","evidence_excerpt":"the Company expects net product sales from continuing operations for the fourth quarter of 2023 to be approximately $40 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2023"},{"label":"Revenue","value":"$15 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"ddf5890e9cfb31c016d19a410a1fb46587e13ff5","claim":"Travere Therapeutics, Inc. reported fourth quarter of 2023 results: revenue $15 million.","evidence_excerpt":"Preliminary net product sales of FILSPARI in the fourth quarter of 2023 were $15 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000119312524003866/0001193125-24-003866-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter of 2023"},{"label":"Revenue","value":"$15 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}